Targeted inhibition of tumor-derived exosomes as a novel therapeutic option for cancer

참고문헌 (134)

1. Yanez-Mo, M., "Biological properties of extracellular vesicles and their physiological functions", J. Extracell. Vesicles, 4, pp.27066~ (2015)
2. Kalluri, R., "The biology function and biomedical applications of exosomes", Science, 367, pp.eaau6977~ (2020)
3. Doyle, L. M., "Overview of extracellular vesicles, their origin, composition, purpose, and methods for exosome isolation and analysis", Cells, 8, pp.727~ (2019)
4. Raposo, G., "Extracellular vesicles : exosomes, microvesicles, and friends", J. Cell Biol, 200, pp.373~383 (2013)
5. Mashouri, L., "Exosomes : composition, biogenesis, and mechanisms in cancer metastasis and drug resistance", Mol. Cancer, 18, pp.75~ (2019)
6. Whiteside, T. L., "Tumor-derived exosomes(TEX)and their role in immuno-oncology", Int. J. Mol. Sci, 22, pp.6234~ (2021)
7. Hoshino, A., "Tumour exosome integrins determine organotropic metastasis", Nature, 527, pp.329~335 (2015)
8. Kim, H., "The emerging roles of exosomes as EMT regulators in cancer", Cells, 9, pp.861~ (2020)
9. Wolf-Dennen, K., "Exosomes : dynamic mediators of extracellular communication in the tumor microenvironment", Adv. Exp. Med. Biol, 1258, pp.189~197 (2020)
10. Zeng, Z., "Cancer-derived exosomal miR-25-3p promotes pre-metastatic niche formation by inducing vascular permeability and angiogenesis", Nat. Commun, 9, pp.5395~ (2018)
11. Whiteside, T. L., "Tumor-derived exosomes and their role in cancer progression", Adv. Clin. Chem, 74, pp.103~141 (2016)
12. Lobb, R. J., "Exosomes: key mediators of metastasis and pre-metastatic niche formation", Semin. Cell Dev. Biol, 67, pp.3~10 (2017)
13. Lei, X., "Immune cells within the tumor microenvironment : biological functions and roles in cancer immunotherapy", Cancer Lett, 470, pp.126~133 (2020)
14. Hinshaw, D. C., "The tumor microenvironment innately modulates cancer progression", Cancer Res, 79, pp.4557~4566 (2019)
15. Abusamra, A. J., "Tumor exosomes expressing Fas ligand mediate CD8+T-cell apoptosis", Blood Cells Mol. Dis, 35, pp.169~173 (2005)
16. Hao, Q., "Tumor-derived exosomes in tumor-induced immune suppression", Int. J. Mol. Sci, 23, pp.1461~ (2022)
17. Whiteside, T. L., "Immune modulation of T-cell and NK(natural killer)cell activities by TEXs(tumour-derived exosomes)", Biochem. Soc. Trans, 41, pp.245~251 (2013)
18. Miyazaki, T., "Extracellular vesiclemediated EBAG9 transfer from cancer cells to tumor microenvironment promotes immune escape and tumor progression", Oncogenesis, 7, pp.7~ (2018)
19. Muller, L., "Tumorderived exosomes regulate expression of immune function-related genes in human T cell subsets", Sci. Rep, 6, pp.20254~ (2016)
20. Schuler, P. J., "Human CD4+ CD39+ regulatory T cells produce adenosine upon co-expression of surface CD73 or contact with CD73+ exosomes or CD73+ cells", Clin. Exp. Immunol, 177, pp.531~543 (2014)
21. Whiteside, T. L., "The effect of tumor-derived exosomes on immune regulation and cancer immunotherapy", Future Oncol, 13, pp.2583~2592 (2017)
22. Liu, C., "Murine mammary carcinoma exosomes promote tumor growth by suppression of NK cell function", J. Immunol, 176, pp.1375~1385 (2006)
23. Zhang, H. G., "Curcumin reverses breast tumor exosomes mediated immune suppression of NK cell tumor cytotoxicity", Biochim. Biophys. Acta, 1773, pp.1116~1123 (2007)
24. Salimu, J., "Dominant immunosuppression of dendritic cell function by prostate-cancer-derived exosomes", J. Extracell. Vesicles, 6, pp.1368823~ (2017)
25. Shen, Y., "Tumor-derived exosomes educate dendritic cells to promote tumor metastasis via HSP72", HSP105-TLR2, Oncoimmunology, pp.2017, 6[DOI]
26. Grange, C., "Role of HLA-G and extracellular vesicles in renal cancer stem cell-induced inhibition of dendritic cell differentiation", BMC Cancer, 15, pp.1009~ (2015)
27. Wu, L., "Exosomes derived from gastric cancer cells activate NF-kappaB pathway in macrophages to promote cancer progression", Tumour Biol, 37, pp.12169~12180 (2016)
28. Wang, X., "Hypoxic tumor-derived exosomal miR-301a mediates M2 macrophage polarization via PTEN", PI3Kgamma to promote pancreatic cancer metastasis, 2018, pp.78, 4586~4598
29. Cheng, Z., "Tumor-derived exosomes induced M2 macrophage polarization and promoted the metastasis of osteosarcoma cells through Tim-3", Arch. Med. Res, 52, pp.200~210 (2021)
30. Roma-Rodrigues, C., "Exosome in tumour microenvironment : overview of the crosstalk between normal and cancer cells", Biomed. Res. Int, 2014, pp.179486~ (2014)
31. Sahai, E., "A framework for advancing our understanding of cancerassociated fibroblasts", Nat. Rev. Cancer, 20, pp.174~186 (2020)
32. Kalluri, R., "The biology and function of fibroblasts in cancer", Nat. Rev. Cancer, 16, pp.582~598 (2016)
33. Webber, J., "Cancer exosomes trigger fibroblast to myofibroblast differentiation", Cancer Res, 70, pp.9621~9630 (2010)
34. Ringuette Goulet, C., "Exosomes induce fibroblast differentiation into cancer-associated fibroblasts through TGFbeta signaling", Mol. Cancer Res, 16, pp.1196~1204 (2018)
35. Sung, J. S., "ITGB4-mediated metabolic reprogramming of cancer-associated fibroblasts", Oncogene, 39, pp.664~676 (2020)
36. Yang, S. S., "Breast cancer-derived exosomes regulate cell invasion and metastasis in breast cancer via miR-146a to activate cancer associated fibroblasts in tumor microenvironment", Exp. Cell Res, 391, pp.111983~ (2020)
37. Ludwig, N., "Exosomes from HNSCC promote angiogenesis through reprogramming of endothelial cells", Mol. Cancer Res, 16, pp.1798~1808 (2018)
38. Skog, J., "Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers", Nat. Cell. Biol, 10, pp.1470~1476 (2008)
39. Park, J. E., "Hypoxic tumor cell modulates its microenvironment to enhance angiogenic and metastatic potential by secretion of proteins and exosomes", Mol. Cell Proteom, 9, pp.1085~1099 (2010)
40. Olejarz, W., "Exosomes in angiogenesis and anti-angiogenic therapy in cancers", Int. J. Mol. Sci, 21, pp.5840~ (2020)
41. Ekstrom, E. J., "WNT5A induces release of exosomes containing proangiogenic and immunosuppressive factors from malignant melanoma cells", Mol. Cancer, 13, pp.88~ (2014)
42. Ludwig, N., "Potential roles of tumor-derived exosomes in angiogenesis", Expert Opin. Ther. Targets, 22, pp.409~417 (2018)
43. Namee, N. M., "Extracellular vesicles and anti-cancer drug resistance", Biochim. Biophys. Acta Rev. Cancer, 1870, pp.123~136 (2018)
44. Li, I., "Exosomes in the tumor microenvironment as mediators of cancer therapy resistance", Mol. Cancer, 18, pp.32~ (2019)
45. Guo, Q. R., "The role of exosomal microRNA in cancer drug resistance", Front. Oncol, 10, pp.472~ (2020)
46. Li, J., "Exosome-derived microRNAs contribute to prostate cancer chemoresistance", Int. J. Oncol, 49, pp.838~846 (2016)
47. Lv, M. M., "Exosomes mediate drug resistance transfer in MCF-7 breast cancer cells and a probable mechanism is delivery of P-glycoprotein", Tumour Biol, 35, pp.10773~10779 (2014)
48. Zeng, A. L., "Tumour exosomes from cells harbouring PTPRZ1-MET fusion contribute to a malignant phenotype and temozolomide chemoresistance in glioblastoma", Oncogene, 36, pp.5369~5381 (2017)
49. Ribas, A., "Cancer immunotherapy using checkpoint blockade", Science, 359, pp.1350~1355 (2018)
50. Minn, A. J., "Combination cancer therapies with immune checkpoint blockade : convergence on interferon signaling", Cell, 165, pp.272~275 (2016)
51. Patel, S. A., "Combination cancer therapy with immune checkpoint blockade : mechanisms and strategies", Immunity, 48, pp.417~433 (2018)
52. Chen, G., "Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response", Nature, 560, pp.382~386 (2018)
53. Poggio, M., "Suppression of exosomal PD-L1 induces systemic anti-tumor immunity and memory", Cell, 177, pp.414~427.e413 (2019)
54. Ricklefs, F. L., "Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles", Sci. Adv, 4, pp.eaar2766~ (2018)
55. Morrissey, S. M., "Exosomal PD-L1 : roles in tumor progression and immunotherapy", Trends Cancer, 6, pp.550~558 (2020)
56. Huotari, J., "Endosome maturation", Embo J, 30, pp.3481~3500 (2011)
57. Juan, T., "Biogenesis and function of ESCRT-dependent extracellular vesicles", Semin. Cell Dev. Biol, 74, pp.66~77 (2018)
58. Wollert, T., "Molecular mechanism of multivesicular body biogenesis by ESCRT complexes", Nature, 464, pp.864~869 (2010)
59. Villarroya-Beltri, C., "ISGylation controls exosome secretion by promoting lysosomal degradation of MVB proteins", Nat. Commun, 7, pp.13588~ (2016)
60. Toyoshima, M., "Inhibition of tumor growth and metastasis by depletion of vesicular sorting protein Hrs : its regulatory role on E-cadherin and beta-catenin", Cancer Res, 67, pp.5162~5171 (2007)
61. Deng, T., "STAM prolongs clear cell renal cell carcinoma patients’ survival via inhibiting cell growth and invasion", Front. Oncol, 11, pp.611081~ (2021)
62. Yang, Y., "STAM2 knockdown inhibits proliferation, migration, and invasion by affecting the JAK2", STAT3 signaling pathway in gastric cancer, 2021, pp.53, 697~706
63. Zhu, Y., "TSG101 promotes the proliferation, migration, and invasion of human glioma cells by regulating the AKT", GSK3beta, Cofilin pathways, pp.Mol. Neurobiol, 2021[DOI]
64. Fujita, K., "Proteomic analysis of urinary extracellular vesicles from high Gleason score prostate cancer", Sci. Rep, 7, pp.42961~ (2017)
65. Zhao, C., "The role of Alix in the proliferation of human glioma cells", Hum. Pathol, 52, pp.110~118 (2016)
66. Colombo, M., "Analysis of ESCRT functions in exosome biogenesis, composition and secretion highlights the heterogeneity of extracellular vesicles", J. Cell Sci, 126, pp.5553~5565 (2013)
67. Bache, K. G., "STAM and Hrs are subunits of a multivalent ubiquitin-binding complex on early endosomes", J. Biol. Chem, 278, pp.12513~12521 (2003)
68. Baietti, M., "Syndecan-syntenin-ALIX regulates the biogenesis of exosomes", Nat. Cell Biol, 14, pp.677~685 (2012)
69. Larios, J., "ALIX-and ESCRT-III-dependent sorting of tetraspanins to exosomes", J. Cell Biol, 219, pp.e201904113~ (2020)
70. Dores, M. R., "ALIX binds a YPX(3)L motif of the GPCR PAR1 and mediates ubiquitin-independent ESCRT-III", MVB sorting, 2012, pp.197, 407~419
71. Monypenny, J., "ALIX regulates tumor-mediated immunosuppression by controlling EGFR activity and PD-L1 presentation", Cell Rep, 24, pp.630~641 (2018)
72. Trajkovic, K., "Ceramide triggers budding of exosome vesicles into multivesicular endosomes", Science, 319, pp.1244~1247 (2008)
73. Skotland, T., "Exosomal lipid composition and the role of ether lipids and phosphoinositides in exosome biology", J. Lipid Res, 60, pp.9~18 (2019)
74. Stenmark, H., "Rab GTPases as coordinators of vesicle traffic", Nat. Rev. Mol. Cell Biol, 10, pp.513~525 (2009)
75. Blanc, L., "New insights into the function of Rab GTPases in the context of exosomal secretion", Small GTPases, 9, pp.95~106 (2018)
76. Ostrowski, M., "Rab27a and Rab27b control different steps of the exosome secretion pathway", Nat. Cell Biol, 12(1), pp.19~30 (2010)
77. Ostenfeld, M. S., "Cellular disposal of miR23b by RAB27-dependent exosome release is linked to acquisition of metastatic properties", Cancer Res, 74, pp.5758~5771 (2014)
78. Abrami, L., "Hijacking multivesicular bodies enables long-term and exosome-mediated long-distance action of anthrax toxin", Cell Rep, 5, pp.986~996 (2013)
79. Südhof, T., "Membrane fusion : grappling with SNARE and SM proteins", Science, 323, pp.474~477 (2009)
80. Hong, W., "Tethering the assembly of SNARE complexes", Trends Cell Biol, 24, pp.35~43 (2014)
81. Peak, T., "Syntaxin 6-mediated exosome secretion regulates enzalutamide resistance in prostate cancer", Mol. Carcinog, 59, pp.62~72 (2020)
82. Ruiz-Martinez, M., "YKT6 expression, exosome release, and survival in nonsmall cell lung cancer", Oncotarget, 7, pp.51515~51524 (2016)
83. Fader, C. M., "TI-VAMP", VAMP7and VAMP3, multivesicular body pathways, pp.Biochim. Biophys. Acta, 2009[DOI]
84. Wu, T., "Tumor microenvironment and therapeutic response", Cancer Lett, 387, pp.61~68 (2017)
85. Xi, L., "Hypoxia-stimulated ATM activation regulates autophagy-associated exosome release from cancer-associated fibroblasts to promote cancer cell invasion", J. Extracell. Vesicles, 10, pp.e12146~ (2021)
86. Parolini, I., "Microenvironmental pH is a key factor for exosome traffic in tumor cells", J. Biol. Chem, 284, pp.34211~34222 (2009)
87. Luo, W., "Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxiainducible factor 1", Cell, 145, pp.732~744 (2011)
88. Wei, Y., "Pyruvate kinase type M2 promotes tumour cell exosome release via phosphorylating synaptosome-associated protein 23", Nat. Commun, 8, pp.14041~ (2017)
89. Prior, I. A., "The frequency of Ras mutations in cancer", Cancer Res, 80, pp.2969~2974 (2020)
90. Sexton, R. E., "Ras and exosome signaling", Semin. Cancer Biol, 54, pp.131~137 (2019)
91. Jouida, A., "Exosomes : a new perspective in EGFR-mutated lung cancer", Cancer Metastasis Rev, 40, pp.589~601 (2021)
92. Boettcher, M., "Choosing the right tool for the job : RNAi, TALEN, or CRISPR", Mol. Cell, 58, pp.575~585 (2015)
93. Hoshino, D., "Exosome secretion is enhanced by invadopodia and drives invasive behavior", Cell Rep, 5, pp.1159~1168 (2013)
94. Ghossoub, R., "Syntenin-ALIX exosome biogenesis and budding into multivesicular bodies are controlled by ARF6 and PLD2", Nat. Commun, 5, pp.3477~ (2014)
95. Sinha, S., "Cortactin promotes exosome secretion by controlling branched actin dynamics", J. Cell Biol, 214, pp.197~213 (2016)
96. Wei, D., "RAB31 marks and controls an ESCRT-independent exosome pathway", Cell Res, 31, pp.157~177 (2021)
97. Shamseddine, A. A., "Roles and regulation of neutral sphingomyelinase-2 in cellular and pathological processes", Adv. Biol. Regul, 57, pp.24~41 (2015)
98. Yang, Y., "Exosomal PD-L1 harbors active defense function to suppress T cell killing of breast cancer cells and promote tumor growth", Cell Res, 28, pp.862~864 (2018)
99. Montermini, L., "Inhibition of oncogenic epidermal growth factor receptor kinase triggers release of exosome-like extracellular vesicles and impacts their phosphoprotein and DNA content", J. Biol. Chem, 290, pp.24534~24546 (2015)
100. Matsumoto, A., "Accelerated growth of B16BL6 tumor in mice through efficient uptake of their own exosomes by B16BL6 cells", Cancer Sci, 108, pp.1803~1810 (2017)
101. Wang, G., "A nanounit strategy reverses immune suppression of exosomal PD-L1 and is associated with enhanced ferroptosis", Nat. Commun, 12, pp.5733~ (2021)
102. Airola, M. V., "Structure of human nSMase2 reveals an interdomain allosteric activation mechanism for ceramide generation", Proc. Natl Acad. Sci. USA, 114, pp.E5549~E5558 (2017)
103. Tschuschke, M., "Inclusion biogenesis, methods of isolation and clinical application of human cellular exosomes", J. Clin. Med, 9, pp.436~ (2020)
104. Yoo, S. W., "Inhibition of neutral sphingomyelinase 2 promotes remyelination", Sci. Adv, 6, pp.eaba5210~ (2020)
105. Datta, A., "Manumycin A suppresses exosome biogenesis and secretion via targeted inhibition of Ras", Raf, 2 signaling and hnRNP H1 in castrationresistant prostate cancer cells, pp.Cancer Lett, 2017[DOI]
106. Datta, A., "High-throughput screening identified selective inhibitors of exosome biogenesis and secretion : a drug repurposing strategy for advanced cancer", Sci. Rep, 8, pp.8161~ (2018)
107. Greenberg, J. W., "Repurposing ketoconazole as an exosome directed adjunct to sunitinib in treating renal cell carcinoma", Sci. Rep, 11, pp.10200~ (2021)
108. Sasabe, E., "Epidermal growth factor", epidermal growth factor receptor signaling blockage inhibits tumor cell-derived exosome uptake by oral squamous cell carcinoma through macropinocytosis, 2022, pp.113, 609~621
109. Wu, X., "Heparan sulfate analogues regulate tumor-derived exosome formation that attenuates exosome functions in tumor processes", Int. J. Biol. Macromol, 187, pp.481~491 (2021)
110. Im, E. J., "Sulfisoxazole inhibits the secretion of small extracellular vesicles by targeting the endothelin receptor A", Nat. Commun, 10, pp.1387~ (2019)
111. Shin, J. M., "Sulfisoxazole elicits robust antitumour immune response along with immune checkpoint therapy by inhibiting exosomal PD-L1", Adv. Sci. (Weinh.), 9, pp.e2103245~ (2022)
112. Orme, J., "Therapeutic plasma exchange clears circulating soluble PD-L1 and PD-L1-positive extracellular vesicles", J. Immunother. Cancer, 8, pp.e001113~ (2020)
113. Wang, L., "Targeting regulation of the tumour microenvironment induces apoptosis of breast cancer cells by an affinity hemoperfusion adsorbent", Artif. Cells Nanomed. Biotechnol, 49, pp.325~334 (2021)
114. Wu, T., "Anticlogging hemofiltration device for mass collection of circulating tumor cells by ligand-free size selection", Langmuir, 37, pp.3399~3409 (2021)
115. Tayebi, M., "Exosome purification and analysis using a facile microfluidic hydrodynamic trapping device", Anal. Chem, 92, pp.10733~10742 (2020)
116. Chen, M., "CRISPR-Cas9 for cancer therapy : opportunities and challenges", Cancer Lett, 447, pp.48~55 (2019)
117. Mourad, N. I., "Gene editing, gene therapy, and cell xenotransplantation:cell transplantation across species", Curr. Transpl. Rep, 4, pp.193~200 (2017)
118. Vakulskas, C. A., "Evaluation and reduction of CRISPR off-target cleavage events", Nucleic Acid Ther, 29, pp.167~174 (2019)
119. Behr, M., "In vivo delivery of CRISPR-Cas9 therapeutics : progress and challenges", Acta Pharm. Sin. B, 11, pp.2150~2171 (2021)
120. Naso, M. F., "Adeno-associated virus(AAV)as a vector for gene therapy", BioDrugs, 31, pp.317~334 (2017)
121. Mingozzi, F., "Therapeutic in vivo gene transfer for genetic disease using AAV : progress and challenges", Nat. Rev. Genet, 12, pp.341~355 (2011)
122. Davis, K. M., "Small molecule-triggered Cas9 protein with improved genome-editing specificity", Nat. Chem. Biol, 11, pp.316~318 (2015)
123. Doench, J. G., "Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9", Nat. Biotechnol, 34, pp.184~191 (2016)
124. Li, D., "Nanoparticles as drug delivery systems of RNAi in cancer therapy", Molecules, 26, pp.2380~ (2021)
125. Shalem, O., "High-throughput functional genomics using CRISPR-Cas9", Nat. Rev. Genet, 16, pp.299~311 (2015)
126. Kotterman, M. A., "Engineering adeno-associated viruses for clinical gene therapy", Nat. Rev. Genet, 15, pp.445~451 (2014)
127. Catalano, M., "Inhibiting extracellular vesicles formation and release : a review of EV inhibitors", J. Extracell. Vesicles, 9, pp.1703244~ (2020)
128. Pushpakom, S., "Drug repurposing : progress, challenges and recommendations", Nat. Rev. Drug Discov, 18, pp.41~58 (2019)
129. Parvathaneni, V., "Drug repurposing: a promising tool to accelerate the drug discovery process", Drug Discov. Today, 24, pp.2076~2085 (2019)
130. Im, E., "Sulfisoxazole inhibits the secretion of small extracellular vesicles by targeting the endothelin receptor A", Nat. Commun, 10, pp.1387~ (2019)
131. Ma, C., "Protein spectrum changes in exosomes after therapeutic plasma exchange in patients with neuromyelitis optica", J. Clin. Apher, 35, pp.206~216 (2020)
132. Lemke, G., "How macrophages deal with death", Nat. Rev. Immunol, 19, pp.539~549 (2019)
133. Gordon, S. R., "PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity", Nature, 545, pp.495~499 (2017)
134. Lu, T., "CD73 in small extracellular vesicles derived from HNSCC defines tumour-associated immunosuppression mediated by macrophages in the microenvironment", J. Extracell. Vesicles, 11, pp.e12218~ (2022)

관련 논문AI추천